| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Biotech | IPO Date | Headquarters | Ticker | Shs Sold | IPO $/Sh | IPO Proceeds | Insider % | Insider Dollars | Insider Optional | IPO SEC Link | Date Founded | Pre-IPO Shares | IPO Pre- Money | Shs Post-IPO | Post IPO Mkt Cap | Most Advanced | Platform | Therapeutic Area | |||||||
2 | Kymera | 21-Aug-20 | Mass | KYMR | 8.68 | $20.00 | $173.60 | Link | 2017 | 34.46 | $689.2 | 43.1 | $862.80 | Preclinical | Protein degradation | Inflammation & cancer | ||||||||||
3 | Harmony Biosciences | 17-Aug-20 | Pennsylvania | HRMY | 5.35 | $24.00 | $128.40 | Link | 2017 | 58.33 | $1,399.9 | 63.7 | $1,528.32 | Mkt | None | CNS, Narcolepsy | ||||||||||
4 | Inhibrx | 17-Aug-20 | SoCal | INBX | 7.00 | $17.00 | $119.00 | Link | 2017 | 29.66 | $504.2 | 36.7 | $623.22 | Phase I | Monoclonals | Cancer MOA | ||||||||||
5 | CureVac | 13-Aug-20 | Germany | CVAC | 13.33 | $16.00 | $213.28 | Link | 2015 | 162.64 | $2,602.2 | 176.0 | $2,815.52 | Phase I | RNA vaccines | Infections | ||||||||||
6 | Checkmate Pharm | 06-Aug-20 | Mass | CMPI | 5.00 | $15.00 | $75.00 | Link | 2015 | 16.44 | $246.6 | 21.4 | $321.60 | Phase II | VLP technology | Cancer MOA | ||||||||||
7 | Freeline | 06-Aug-20 | England | FRLN | 8.82 | $18.00 | $158.76 | 5% | $7.94 | Yes | Link | 2015 | 17.10 | $307.8 | 25.9 | $466.56 | Phase I/II | Gene Therapy | Blood disorders | |||||||
8 | AlloVir | 29-Jul-20 | Mass | ALVR | 16.25 | $17.00 | $276.25 | Link | 2013 | 46.42 | $789.1 | 62.7 | $1,065.39 | Phase II | cell therapy | Antivirals | ||||||||||
9 | Annexon | 23-Jul-20 | NorCal | ANNX | 14.75 | $17.00 | $250.75 | Link | 2011 | 21.25 | $361.3 | 36.0 | $612.00 | Phase I | Complement inhib | Autoimmune & CNS | ||||||||||
10 | Inozyme Pharma | 23-Jul-20 | Mass | INZY | 7.00 | $16.00 | $112.00 | Link | 2015 | 15.31 | $245.0 | 22.3 | $356.96 | Preclinical | None | Genetic diseases | ||||||||||
11 | iTeos Therapeutics | 23-Jul-20 | Mass/Belgium | ITOS | 10.59 | $19.00 | $201.21 | Link | 2011 | 22.84 | $434.0 | 33.4 | $635.17 | Phase I | Drug design | Cancer MOA | ||||||||||
12 | Nurix Therapeutics | 23-Jul-20 | NorCal | NRIX | 11.00 | $19.00 | $209.00 | Link | 2009 | 26.04 | $494.8 | 37.0 | $703.76 | Preclinical | Drug design | Cancer MOA | ||||||||||
13 | ALX Oncology | 16-Jul-20 | NorCal/Ireland | ALXO | 8.50 | $19.00 | $161.50 | Link | 2015 | 26.71 | $507.5 | 35.2 | $668.99 | Phase I | Drug design | Cancer MOA | ||||||||||
14 | Berkeley Lights | 16-Jul-20 | NorCal | BLI | 8.10 | $22.00 | $178.20 | Link | 2011 | 53.54 | $1,177.9 | 61.6 | $1,356.08 | Mkt | Cell biology | Reagents | ||||||||||
15 | Pandion Therapeutics | 16-Jul-20 | Mass | PAND | 7.50 | $18.00 | $135.00 | Link | 2016 | 21.03 | $378.5 | 28.5 | $513.54 | Phase I | Drug design | Autoimmune | ||||||||||
16 | Renalytix AI plc | 16-Jul-20 | New York/UK | RLNX | 11.00 | $6.75 | $74.25 | Link | 2018 | 59.42 | $401.1 | 70.4 | $475.34 | Mkt | Diagnostic | Kidney disease | ||||||||||
17 | Relay Therapeutics | 15-Jul-20 | Mass | RLAY | 20.00 | $20.00 | $400.00 | Link | 2015 | 66.88 | $1,337.6 | 86.9 | $1,737.60 | Phase I | Drug design | Cancer MOA | ||||||||||
18 | Inventiva | 09-Jul-20 | France | IVA | 7.48 | $14.40 | $107.71 | Link | 2011 | 30.69 | $441.9 | 38.2 | $549.65 | Phase II | None | Liver disease, Genetic | ||||||||||
19 | Nkarta | 09-Jul-20 | NorCal | NKTX | 14.00 | $18.00 | $252.00 | Link | 2015 | 16.43 | $295.7 | 30.4 | $547.74 | Preclinical | cell therapy | Cancer MOA | ||||||||||
20 | Poseida Therapeutics | 09-Jul-20 | SoCal | PSTX | 14.00 | $16.00 | $224.00 | Link | 2014 | 47.82 | $765.1 | 61.8 | $989.12 | Phase II | Cell & gene therapy | Cancer | ||||||||||
21 | Akouos | 25-Jun-20 | Mass | AKUS | 12.50 | $17.00 | $212.50 | Link | 2016 | 19.98 | $339.7 | 32.5 | $552.16 | Preclinical | Gene Therapy | Ear, Nose, Throat | ||||||||||
22 | Fusion Pharmaceuticals | 25-Jun-20 | Ontario | FUSN | 12.50 | $17.00 | $212.50 | Link | 2014 | 29.16 | $495.7 | 41.7 | $708.22 | Phase I | radiotherapy | Cancer | ||||||||||
23 | PolyPid | 25-Jun-20 | Israel | PYPD | 3.75 | $16.00 | $60.00 | 45% | $27.00 | Yes | Link | 2008 | 13.30 | $212.8 | 17.1 | $272.80 | Phase III | Formulation | Multiple | |||||||
24 | Progenity | 19-Jun-20 | SoCal | PROG | 6.67 | $15.00 | $100.05 | 50% | $50.03 | Link | 2012 | 38.49 | $577.4 | 45.2 | $677.40 | Mkt | None | Diagnostics | ||||||||
25 | Forma Therapeutics | 18-Jun-20 | Mass | FMTX | 13.88 | $20.00 | $277.60 | Link | 2011 | 25.12 | $502.4 | 39.0 | $780.00 | Phase II | None | Cancer & genetic | ||||||||||
26 | Genetron Holdings | 18-Jun-20 | China | GTH | 80.00 | $3.20 | $256.00 | 8% | $20.48 | Link | 2015 | 361.81 | $1,157.8 | 441.8 | $1,413.79 | Mkt | Diagnostic | Cancer | ||||||||
27 | Repare Therapeutics | 18-Jun-20 | Quebec | RPTX | 11.00 | $20.00 | $220.00 | Link | 2016 | 24.02 | $480.4 | 35.0 | $700.40 | Preclinical | Gene profiles | Cancer MOA | ||||||||||
28 | Royalty Pharma | 15-Jun-20 | New York | RPRX | 60.00 | $28.00 | $1,680.00 | Link | 1996 | 535.39 | $14,990.9 | 595.4 | $16,670.92 | Mkt | None | Multiple | ||||||||||
29 | Avidity Biosciences | 11-Jun-20 | SoCal | RNA | 14.40 | $18.00 | $259.20 | Link | 2012 | 20.95 | $377.1 | 35.4 | $636.30 | Preclinical | Oligo-Antibodies | Genetic diseases | ||||||||||
30 | Burning Rock Biotech | 11-Jun-20 | China | BNR | 13.50 | $16.50 | $222.75 | 35% | $77.96 | Link | 2014 | 88.28 | $1,456.6 | 101.8 | $1,679.37 | Mkt | None | Diagnostics, Cancer | ||||||||
31 | Generation Bio | 11-Jun-20 | Mass | GBIO | 10.53 | $19.00 | $199.99 | Link | 2016 | 34.10 | $647.9 | 44.6 | $847.89 | Preclinical | Gene Therapy | Liver disease, Eye | ||||||||||
32 | Vaxcyte | 11-Jun-20 | NorCal | PCVX | 15.63 | $16.00 | $250.00 | Link | 2013 | 32.76 | $524.2 | 48.4 | $774.16 | Preclinical | Vaccine design | Infections | ||||||||||
33 | Lantern Pharma | 10-Jun-20 | Dallas | LTRN | 1.75 | $15.00 | $26.25 | Link | 2013 | 4.47 | $67.1 | 6.2 | $93.30 | Phase II | Bioinformatics | Cancer | ||||||||||
34 | Legend Biotech | 08-Jun-20 | New Jersey | LEGN | 36.85 | $11.50 | $423.78 | Link | 2014 | 221.64 | $2,548.9 | 258.5 | $2,972.64 | Phase II | cell therapy | Cancer MOA | ||||||||||
35 | Applid Molecular Transport | 04-Jun-20 | NorCal | AMTI | 11.00 | $14.00 | $154.00 | Link | 2010 | 21.40 | $299.6 | 32.4 | $453.60 | Phase I | Active cell transport | Gastrointestinal | ||||||||||
36 | Calliditas Therapeutics | 04-Jun-20 | Sweden | CALT | 9.23 | $9.75 | $89.99 | Link | 2004 | 38.71 | $377.4 | 47.9 | $467.42 | Phase III | None | Orphan diseases | ||||||||||
37 | Pliant Therapeutics | 03-Jun-20 | NorCal | PLRX | 9.63 | $16.00 | $154.00 | Link | 2015 | 24.58 | $393.3 | 34.2 | $547.28 | Phase II | None | Liver disease | ||||||||||
38 | ADC Therapeutics | 14-May-20 | Switzerland | ADCT | 12.25 | $19.00 | $232.75 | No Amt | Link | 2011 | 56.64 | $1,076.2 | 68.9 | $1,308.91 | Phase II | Ab conjugates | Cancer MOA | |||||||||
39 | Ayala Pharmaceuticals | 07-May-20 | Israel | AYLA | 3.67 | $15.00 | $55.01 | Link | 2017 | 8.78 | $131.7 | 12.4 | $186.71 | Phase II | Notch pathway | Cancer MOA | ||||||||||
40 | Lyra Therapeutics | 30-Apr-20 | Mass | LYRA | 3.50 | $16.00 | $56.00 | Link | 2005 | 8.90 | $142.4 | 12.4 | $198.40 | Phase II | ENT delivery | Ear, Nose, Throat | ||||||||||
41 | Oric Pharmaceuticals | 23-Apr-20 | NorCal | ORIC | 7.50 | $16.00 | $120.00 | Link | 2014 | 21.29 | $340.6 | 28.8 | $460.64 | Phase I | Drug design | Cancer MOA | ||||||||||
42 | Keros Therapeutics | 07-Apr-20 | Mass | KROS | 6.00 | $16.00 | $96.00 | Link | 2015 | 13.19 | $211.0 | 19.2 | $307.04 | Phase I | TGFbeta signaling | Blood disorders | ||||||||||
43 | Zentalis Pharmaceuticals | 02-Apr-20 | New York | ZNTL | 9.18 | $18.00 | $165.24 | Link | 2014 | 25.32 | $455.8 | 34.5 | $621.00 | Phase I | Drug design | Cancer MOA | ||||||||||
44 | IMARA | 11-Mar-20 | Mass | IMRA | 4.70 | $16.00 | $75.20 | Link | 2016 | 11.88 | $190.1 | 16.6 | $265.28 | Phase II | None | Genetic diseases | ||||||||||
45 | Passage BIO | 27-Feb-20 | Philadelphia | PASG | 12.00 | $18.00 | $216.00 | Link | 2017 | 32.00 | $576.0 | 44.0 | $792.00 | Preclinical | Gene Therapy | CNS | ||||||||||
46 | Revolution Medicines | 12-Feb-20 | NorCal | RVMD | 14.00 | $17.00 | $238.00 | Link | 2014 | 42.90 | $729.3 | 56.9 | $967.30 | Phase I | Drug design | Cancer MOA | ||||||||||
47 | Beam Therapeutics | 05-Feb-20 | Mass | BEAM | 10.59 | $17.00 | $180.03 | Link | 2017 | 39.07 | $664.2 | 49.7 | $844.22 | Lead | Gene editing | Multiple | ||||||||||
48 | PPD | 05-Feb-20 | N Carolina | PPD | 60.00 | $27.00 | $1,620.00 | 2% | $32.40 | Yes | Link | 2017 | 279.43 | $7,544.6 | 339.4 | $9,164.61 | Mkt | None | CRO | |||||||
49 | Schrodinger | 05-Feb-20 | New York | SDGR | 11.88 | $17.00 | $201.96 | Link | 1990 | 49.57 | $842.7 | 61.5 | $1,044.65 | Mkt | Bioinformatics | Software | ||||||||||
50 | Arcutis Biotherapeutics | 30-Jan-20 | SoCal | ARQT | 9.38 | $17.00 | $159.46 | 31% | $49.43 | Yes | Link | 2016 | 27.25 | $463.3 | 36.6 | $622.71 | Phase III | None | Dermatology | |||||||
51 | Annovis Bio | 29-Jan-20 | Pennsylvania | ANVS | 2.00 | $6.00 | $12.00 | 7% | $0.80 | Yes | Link | 2008 | 4.52 | $27.1 | 6.5 | $39.12 | Phase II | Drug design | CNS | |||||||
52 | Black Diamond Therapeutics | 29-Jan-20 | Mass | BDTX | 10.59 | $19.00 | $201.21 | Link | 2014 | 23.73 | $450.9 | 34.3 | $652.08 | Preclinical | Drug design | Cancer MOA | ||||||||||
53 | AnPac Bio-Medical Sci | 28-Jan-20 | China | ANPC | 1.33 | $12.00 | $15.96 | 11% | $1.74 | Link | 2010 | 9.87 | $118.4 | 11.2 | $134.40 | Mkt | None | Diagnostics, Cancer | ||||||||
54 | I-Mab Biopharma | 16-Jan-20 | China | IMAB | 17.04 | $6.09 | $103.72 | 28% | $28.73 | Link | 2014 | 114.20 | $695.1 | 131.2 | $798.86 | Phase III | None | Cancer & Autoimmune | ||||||||
55 | Galera Therapeutics | 12-Nov-19 | Pennsylvania | GRTX | 5.00 | $12.00 | $60.00 | 67% | $39.96 | Yes | Link | 2012 | 19.36 | $232.3 | 24.4 | $292.32 | Phase III | radiotherapy | Cancer | |||||||
56 | 89Bio | 11-Nov-19 | Israel/NorCal | ETNB | 5.30 | $16.00 | $84.80 | 60% | $50.88 | Link | 2018 | 7.69 | $123.0 | 13.0 | $207.84 | Phase I | None | Liver disease | ||||||||
57 | CNS Pharmaceuticals | 07-Nov-19 | Texas | CNSP | 2.13 | $4.00 | $8.50 | Link | 2017 | 13.59 | $54.4 | 15.7 | $62.86 | Preclinical | None | Cancer | ||||||||||
58 | TELA Bio | 07-Nov-19 | Pennsylvania | TELA | 4.00 | $13.00 | $52.00 | Link | 2012 | 7.01 | $91.1 | 11.0 | $143.13 | Mkt | None | Dermatology, Tissue reconstruction | ||||||||||
59 | Centogene B.V. | 06-Nov-19 | Germany | CNTG | 4.00 | $14.00 | $56.00 | 54% | $30.02 | Link | 2018 | 15.86 | $222.0 | 19.9 | $278.04 | Mkt | Bioinformatics | Genetic diseases | ||||||||
60 | Oyster Point Pharma | 30-Oct-19 | New Jersey | OYST | 5.00 | $16.00 | $80.00 | Link | 2015 | 15.61 | $249.8 | 20.6 | $329.76 | Phase III | None | Eye diseases | ||||||||||
61 | RAPT Therapeutics | 30-Oct-19 | NorCal | RAPT | 3.00 | $12.00 | $36.00 | 44% | $15.70 | Link | 2015 | 18.28 | $219.4 | 21.3 | $255.36 | Phase I | Drug design | Cancer MOA | ||||||||
62 | Happiness Biotech Group | 25-Oct-19 | China | HAPP | 2.00 | $5.50 | $11.00 | Link | 2004 | 23.00 | $126.5 | 25.0 | $137.50 | Mkt | None | Nutriceuticals | ||||||||||
63 | Cabaletta Bio | 24-Oct-19 | Philadelphia | CABA | 6.80 | $11.00 | $74.80 | 5% | $3.74 | Yes | Link | 2017 | 16.75 | $184.3 | 23.6 | $259.05 | Phase I | cell therapy | Autoimmune | |||||||
64 | Phathom Pharm | 24-Oct-19 | Illinois | PHAT | 9.56 | $19.00 | $181.64 | Link | 2018 | 17.99 | $341.8 | 27.6 | $523.45 | Phase II | None | Gastrointestinal | ||||||||||
65 | Innate Pharma | 16-Oct-19 | France | IPHA | 12.50 | $5.50 | $68.75 | Link | 1999 | 64.04 | $352.2 | 76.5 | $420.97 | Mkt | Monoclonals | Cancer | ||||||||||
66 | Vir Biotechnology | 10-Oct-19 | NorCal | VIR | 7.14 | $20.00 | $142.80 | Link | 2016 | 102.26 | $2,045.2 | 109.4 | $2,188.00 | Phase II | Monoclonals & RNAi | Infections | ||||||||||
67 | BioNTech | 09-Oct-19 | Germany | BNTX | 10.00 | $15.00 | $150.00 | Link | 2008 | 216.26 | $3,243.9 | 226.3 | $3,393.90 | Phase II | Immunotherapy | Cancer | ||||||||||
68 | Aprea Therapeutics | 02-Oct-19 | Sweden/Mass | APRE | 5.67 | $15.00 | $85.05 | Link | 2002 | 14.21 | $213.2 | 19.9 | $298.20 | Phase III | None | Cancer MOA | ||||||||||
69 | Frequency Therapeutics | 02-Oct-19 | Mass | FREQ | 6.00 | $14.00 | $84.00 | Link | 2014 | 24.45 | $342.3 | 30.5 | $426.30 | Phase I | cell therapy | Multiple | ||||||||||
70 | Viela Bio | 02-Oct-19 | Maryland | VIE | 7.90 | $19.00 | $150.10 | 47% | $69.95 | Link | 2017 | 41.77 | $793.6 | 49.7 | $943.73 | Filed | Monoclonals | Autoimmune | ||||||||
71 | Exagen Diagnostics | 18-Sep-19 | SoCal | XGN | 3.60 | $14.00 | $50.40 | 24% | $12.00 | Yes | Link | 2002 | 7.89 | $110.5 | 11.5 | $160.86 | Mkt | Diagnostic | Autoimmune | |||||||
72 | IGM Biosciences | 17-Sep-19 | NorCal | IGMS | 10.94 | $16.00 | $175.04 | Link | 1993 | 17.95 | $287.2 | 28.9 | $462.24 | Preclinical | Monoclonals | Cancer | ||||||||||
73 | Satsuma Pharmaceuticals | 12-Sep-19 | NorCal | STSA | 5.50 | $15.00 | $82.50 | 30% | $25.00 | Link | 2016 | 11.11 | $166.7 | 16.6 | $249.15 | Phase III | None | CNS, Migraines | ||||||||
74 | SpringWorks Therapeutics | 12-Sep-19 | Connecticut | SWTX | 9.00 | $18.00 | $162.00 | Link | 2017 | 32.88 | $591.8 | 41.9 | $753.84 | Phase III | None | Cancer | ||||||||||
75 | 10x Genomics | 11-Sep-19 | NorCal | TXG | 10.00 | $39.00 | $390.00 | Link | 2012 | 83.85 | $3,270.2 | 93.9 | $3,660.15 | Mkt | Bioinformatics | Instrumentation | ||||||||||
76 | Castle Biosciences | 24-Jul-19 | Texas | CSTL | 4.00 | $16.00 | $64.00 | 23% | $14.98 | Yes | Link | 2007 | 12.05 | $192.8 | 16.1 | $256.80 | Mkt | Gene profiles | Diagnostics, Cancer | |||||||
77 | Genmab | 22-Jul-19 | Denmark | GMAB | 2.85 | $177.50 | $505.88 | Link | 1998 | 61.52 | $10,919.8 | 64.4 | $11,425.68 | Phase II | Monoclonals | Cancer | ||||||||||
78 | Fulcrum Therapeutics | 17-Jul-19 | Mass | FULC | 4.50 | $16.00 | $72.00 | Link | 2015 | 18.84 | $301.4 | 23.3 | $373.44 | Phase I | Cell screening | Genetic diseases | ||||||||||
79 | Mirum Pharmaceuticals | 17-Jul-19 | NorCal | MIRM | 5.00 | $15.00 | $75.00 | 47% | $35.03 | Yes | Link | 2018 | 18.02 | $270.3 | 23.0 | $345.30 | Phase III | None | Liver disease | |||||||
80 | Karuna Therapeutics | 27-Jun-19 | Mass | KRTX | 5.58 | $16.00 | $89.28 | 34% | $30.00 | Yes | Link | 2009 | 17.00 | $272.0 | 22.6 | $361.28 | Phase II | None | CNS Psychiatric | |||||||
81 | Adaptive Biotechnologies | 26-Jun-19 | Seattle | ADPT | 15.00 | $20.00 | $300.00 | Link | 2009 | 105.97 | $2,119.4 | 121.0 | $2,419.40 | Mkt | Bioinformatics | Diagnostics | ||||||||||
82 | BridgeBio Pharma | 26-Jun-19 | NorCal | BBIO | 20.50 | $17.00 | $348.50 | Link | 2015 | 100.00 | $1,700.0 | 120.5 | $2,048.50 | Phase III | Genetic diseases | Multiple | ||||||||||
83 | Morphic Holding | 26-Jun-19 | Mass | MORF | 6.00 | $15.00 | $90.00 | 33% | $29.97 | Yes | Link | 2014 | 23.60 | $354.0 | 29.6 | $444.00 | Preclinical | Integrin biology | Autoimmune | |||||||
84 | Akero Therapeutics | 19-Jun-19 | NorCal | AKRO | 5.75 | $16.00 | $92.00 | 33% | $29.99 | Yes | Link | 2017 | 21.30 | $340.8 | 27.1 | $432.80 | Phase II | None | Liver disease | |||||||
85 | Atreca | 19-Jun-19 | NorCal | BCEL | 7.35 | $17.00 | $124.95 | 50% | $62.97 | Link | 2010 | 19.43 | $330.3 | 26.8 | $455.26 | Preclinical | Monoclonals | Cancer | ||||||||
86 | Personalis | 19-Jun-19 | NorCal | PSNL | 7.92 | $17.00 | $134.64 | Link | 2011 | 21.83 | $371.1 | 29.8 | $505.75 | Mkt | Bioinformatics | Diagnostics, Cancer | ||||||||||
87 | Prevail Therapeutics | 19-Jun-19 | New York | PRVL | 7.35 | $17.00 | $124.95 | Link | 2017 | 26.65 | $453.1 | 34.0 | $578.00 | Preclinical | Gene Therapy | CNS | ||||||||||
88 | Stoke Therapeutics | 18-Jun-19 | Mass | STOK | 7.89 | $18.00 | $142.02 | Link | 2014 | 23.57 | $424.3 | 31.5 | $566.28 | Preclinical | Antisense | Genetic diseases | ||||||||||
89 | Bicycle Therapeutics | 22-May-19 | England | BCYC | 4.33 | $14.00 | $60.62 | 41% | $24.98 | Yes | Link | 2009 | 13.37 | $187.2 | 17.7 | $247.80 | Phase I | Peptides | Cancer MOA | |||||||
90 | IDEAYA Biosciences | 22-May-19 | NorCal | IDYA | 5.00 | $10.00 | $50.00 | 60% | $30.00 | Link | 2015 | 14.48 | $144.8 | 19.5 | $194.80 | Phase I | Drug design | Cancer MOA | ||||||||
91 | Axcella Health | 08-May-19 | Mass | AXLA | 3.57 | $20.00 | $71.40 | 55% | $38.98 | Yes | Link | 2008 | 19.42 | $388.4 | 23.0 | $459.80 | Preclinical | None | Liver disease | |||||||
92 | Cortexyme | 08-May-19 | NorCal | CRTX | 4.41 | $17.00 | $74.97 | 35% | $26.31 | Link | 2012 | 21.60 | $367.2 | 26.0 | $442.17 | Phase I | None | CNS, Alzheimer's | ||||||||
93 | Milestone Pharmaceuticals | 08-May-19 | Quebec | MIST | 5.50 | $15.00 | $82.50 | Link | 2003 | 18.15 | $272.3 | 23.7 | $354.75 | Phase III | None | Cardio | ||||||||||
94 | NextCure | 08-May-19 | Maryland | NXTC | 5.00 | $15.00 | $75.00 | 43% | $32.03 | Link | 2015 | 16.94 | $254.1 | 21.9 | $329.10 | Phase I | Immunotherapy | Cancer | ||||||||
95 | Trevi Therapeutics | 07-May-19 | Connecticut | TRVI | 5.50 | $10.00 | $55.00 | 55% | $29.98 | Yes | Link | 2011 | 10.77 | $107.7 | 16.3 | $162.70 | Phase III | None | CNS & Respiratory | |||||||
96 | HOOKIPA Pharma | 17-Apr-19 | Austria/NY | Hook | 6.00 | $14.00 | $84.00 | 66% | $55.02 | Yes | Link | 2011 | 19.41 | $271.7 | 25.4 | $355.74 | Phase II | Gene Therapy | Antivirals & I/O | |||||||
97 | Turning Point Therapeutics | 16-Apr-19 | SoCal | TPTX | 9.25 | $18.00 | $166.50 | 29% | $48.29 | Link | 2013 | 20.40 | $367.2 | 29.7 | $533.70 | Phase I | Drug design | Cancer MOA | ||||||||
98 | Precision BioSciences | 27-Mar-19 | Durham, NC | DTIL | 7.90 | $16.00 | $126.40 | Link | 2006 | 41.13 | $658.1 | 49.0 | $784.48 | Preclinical | Genome editing | Cancer & genetic | ||||||||||
99 | Genfit | 26-Mar-19 | Loos, France | GNFT | 6.65 | $20.32 | $135.13 | Link | 1999 | 31.18 | $633.6 | 37.8 | $768.71 | Phase III | None | Endocrine, Liver | ||||||||||
100 | Kaleido Biosciences | 27-Feb-19 | Mass | KLDO | 5.00 | $15.00 | $75.00 | Link | 2015 | 24.63 | $369.5 | 29.6 | $444.45 | Preclinical | Microbiome | Endocrine |